UBS Group
TRDA icon

UBS Group’s Entrada Therapeutics TRDA Stock Holding History

UBS Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
41,564
+9,583
+30% +$91.9K ﹤0.01% 6532
2026
Q1 		$404K Buy
31,981
+12,945
+68% +$148K ﹤0.01% 6230
2025
Q4 		$196K Buy
19,036
+126
+0.7% +$1.06K ﹤0.01% 6589
2025
Q3 		$110K Sell
18,910
-5,849
-24% -$34.2K ﹤0.01% 7053
2025
Q2 		$166K Sell
24,759
-26,280
-51% -$211K ﹤0.01% 6841
2025
Q1 		$461K Sell
51,039
-2,052
-4% -$25.6K ﹤0.01% 5912
2024
Q4 		$918K Buy
53,091
+28,100
+112% +$509K ﹤0.01% 5373
2024
Q3 		$399K Buy
24,991
+3,176
+15% +$50K ﹤0.01% 5387
2024
Q2 		$311K Sell
21,815
-1,654
-7% -$23.5K ﹤0.01% 5370
2024
Q1 		$333K Buy
23,469
+993
+4% +$14K ﹤0.01% 5501
2023
Q4 		$339K Buy
22,476
+9,165
+69% +$136K ﹤0.01% 5412
2023
Q3 		$210K Sell
13,311
-377
-3% -$5.94K ﹤0.01% 5335
2023
Q2 		$207K Buy
13,688
+12,231
+839% +$169K ﹤0.01% 5454
2023
Q1 		$21.1K Buy
1,457
+200
+16% +$2.67K ﹤0.01% 7037
2022
Q4 		$17K Buy
+1,257
New +$22K ﹤0.01% 7864
2022
Q3 		– Sell
-597
Closed -$8K – 10934
2022
Q2 		$8K Sell
597
-850
-59% -$6.45K ﹤0.01% 8353
2022
Q1 		$13K Sell
1,447
-1,367
-49% -$14.7K ﹤0.01% 8082
2021
Q4 		$48K Buy
+2,814
New +$68.2K ﹤0.01% 6942

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

UBS Group's TRDA Position: Q2 2026 in Review

UBS Group increased its Entrada Therapeutics (TRDA) stake by 30% in Q2 2026, buying an estimated $91.9K and bringing the position to 41,564 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #6532.

UBS Group first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $918K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • UBS Group held 41,564 shares of Entrada Therapeutics worth $306K as of Q2 2026.
  • UBS Group bought 9,583 Entrada Therapeutics shares in Q2 2026, an estimated $91.9K.
  • Entrada Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6532 holding.
  • UBS Group first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • UBS Group's Entrada Therapeutics position peaked at $918K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.